Management of LSIL with High-Risk HPV

Initial Management Strategy

The American College of Obstetricians and Gynecologists recommends immediate colposcopy for women with LSIL cytology and high-risk HPV, as HPV testing does not provide useful triage, with approximately 80-86% of LSIL cases being HR-HPV positive 1, 2
The presence of high-risk HPV does not change the initial management algorithm because LSIL is almost synonymous with HPV infection, with 80-85% being HR-HPV positive 1
The American Society for Colposcopy and Cervical Pathology recommends colposcopy as the standard of care for all adult women with LSIL cytology, regardless of HPV status 2

The American College of Obstetricians and Gynecologists recommends conservative follow-up rather than immediate treatment for patients with CIN 1 or negative colposcopy, as over 90% of LSIL lesions regress spontaneously within 24 months 3, 4, 2
Two acceptable follow-up options exist: repeat cervical cytology every 6-12 months 3, 2 or HPV DNA testing at 12 months 3, 2
If colposcopy confirms CIN 1 and persists for at least 2 years, treatment should be considered, with either excision or ablation being acceptable if colposcopy is satisfactory 3

For patients under 21 years, the American College of Obstetricians and Gynecologists recommends repeat cytology at 12 months rather than immediate colposcopy, due to high spontaneous regression rates and low risk of invasive cervical cancer 6, 2, 5
HIV-positive or immunocompromised women require more aggressive surveillance, with cervical cytology screening twice within the first year after HIV diagnosis and annual screening thereafter 6

The guidelines cited are from the 2006 ASCCP consensus and remain the foundation of current practice, with high spontaneous regression rates and low progression risk of CIN 1 justifying conservative management regardless of HR-HPV status 3, 4, 7